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Background: Microvascular and macrovascular complications in diabetes stem from chronic hyperglycemia and are
thought to have overlapping pathophysiology. The aim of this study was to investigate the incidence rate of
hospitalized myocardial infarctions (MI) and cerebrovascular accidents (CVA) in patients with diabetic macular
edema (DME) compared with diabetic patients without retinal diseases.
Methods: This was a retrospective cohort study of a commercially insured population in an administrative claims
database. DME subjects (n = 3519) and diabetes controls without retinal disease (n = 10557) were matched by age
and gender. Healthcare claims were analyzed for the study period from 1 January 2002 to 31 December 2005.
Incidence and adjusted rate ratios of hospitalized MI and CVA events were then calculated.
Results: The adjusted rate ratio for MI was 2.50 (95% CI: 1.83-3.41, p< 0.001) for DME versus diabetes controls.
Predictors of MI events were heart disease, history of acute MI, and prior use of antiplatelet or anticoagulant drugs.
The adjusted rate ratio for CVA was 1.98 (95% CI: 1.39-2.83, p< 0.001) for DME versus diabetes controls. Predictors of
CVA events were cardiac arrhythmia, Charlson comorbidity scores, history of CVA, hyperlipidemia, and other
cerebrovascular diseases.
Conclusion: Event rates of MI or CVA were higher in patients with DME than in diabetes controls. This study is one
of few with sufficient sample size to accurately estimate the relationship between DME and cardiovascular
outcomes.Background
Diabetic macular edema (DME) may occur at any stage
of diabetic retinopathy (DR) and is the leading cause of
moderate vision loss in adults of working age [1]. The
prevalence of DME is about one-tenth that of back-
ground DR and one-third that of proliferative DR [2].
Microvascular complications, like DR and DME, are
associated with progressive or uncontrolled diabetes.
Cardiovascular events, such as myocardial infarctions
(MI) or cerebrovascular accidents (CVA)/stroke, are
known macrovascular complications of diabetes mellitus.
Microvascular complications of diabetes are commonly
diagnosed as eye diseases; however, pathologic changes
to cardiac and cerebral circulation also occur [3].* Correspondence: bnguyen@deggegroup.com
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distribution, and reproduction in any mediumThe association between DR and cardiovascular out-
comes has been extensively studied [4-8] and reviewed
[9]. However, cardiovascular outcomes in DME patients
have not been well examined; previously published stud-
ies with DME subjects did not have the power to
characterize the relationship between DR and cardiovas-
cular outcomes [6,10,11]. This report describes research
in a large insured population with sufficient size to quan-
tify and compare the incidence rates of MI or CVA in
patients with DME against matched diabetes controls.
The authors hypothesized that the presence of DME
would be associated with higher rates of MI and CVA.Methods
Database
The Ingenix LabRx Database™ (LabRx) contains adminis-
trative claims data for an employed, commercially
insured population in the USA who are enrolled in 11
health insurance plans affiliated with the UnitedHealthentral Ltd. This is an Open Access article distributed under the terms of the
creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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ence of approximately 14 million patients annually. The
health plans are geographically diverse, with the largest
proportion of patients found in the Midwest of the USA.
Complete pharmacy and medical claims data (including
Medicare and Medicaid) were available for all the
patients in this study.
The study involved the analysis of existing medical
claims records that are recorded in such a manner that
subjects cannot be identified directly or indirectly by the
investigators. It met the exemption criteria for research
activities not requiring institutional review under Title
45 Code of Federal Regulations Part 46.101 of the Basic
HHS Policy for Protection of Human Research Subjects.
Study design
A retrospective cohort study design was used to compare
incidence rates of hospitalized MI and CVA in patients
with DME and diabetic patients without retinal disease.
Claims were analyzed for the 4-year period from 1 Janu-
ary 2002 to 31 December 2005.
Study sample
DME patients
Patients were classified as having DME if they had med-
ical claims for any combination of the following Inter-
national Classification of Diseases, 9th Revision, Clinical
Modification (ICD-9-CM) codes, in order of greater
specificity:
1. 362.07 (DME) AND any code within the range of
362.01-362.06 (background DR). This 362.07 code
combination was added for 2006 [12].
2. 362.83 (retinal edema) AND 250.5x (diabetes with
ophthalmic manifestations) [2].
DME was classified using the ICD-9-CM code 362.01
from 2000 to 2005 [13]. During this period, this code
was also used for DR. To test the ability of this code to
accurately identify subjects with DME, three independ-
ent ophthalmologists were asked to evaluate 148 ran-
domly selected administrative claims profiles of subjects
identified with an ICD-9-CM code of 362.01 (back-
ground DR) and 250.5x (diabetes with ophthalmic mani-
festations) in the same eligibility period. An additional
44 profiles meeting definitions 1 and 2 were evaluated by
each expert (five profiles with 362.07 and 39 profiles with
362.83). The percent agreement between all the
reviewers was 2.7% for profiles with ICD-9-CM 362.01
for the definition of DME. Agreement for ICD-9-CM
362.07 and 362.83 was 100% and 90.7%, respectively.
The ICD-9-CM code 362.01 in combination with 250.5x
was judged to be non-specific for DME and therefore
was excluded from the study.A defined DME diagnosis had to appear at least once
during a continuous eligibility period of> 183 days be-
tween 1 January 2002 and 31 December 2005. The index
date was defined as the date of the first occurrence of
ICD-9-CM codes 362.07 or 362.83 within the code com-
bination sets above, following a minimum of at least
6 months (183 days) of baseline observation. Patients
were included if they were at least 18 years old at the
index date.
For an estimated sample of 3,000 subjects with DME,
there was over 80% power to detect a hazard ratio of at
least 1.25 with 95% confidence (i.e., 25% increased risk of
a CV event) within either group.
Control patients
A set of control subjects with diabetes but without oph-
thalmic complications (ICD-9-CM 250.xx but excluding
250.5x), and without evidence of coding for DME during
the study period were selected. Controls were excluded if
coded for 362.x (other retinal disorders) or 379.23 (vitre-
ous hemorrhage). Three controls were randomly selected
without replacement for each identified DME patient.
Patients were matched by gender and age using the fol-
lowing fixed ranges: 18–25, 26–30, 31–35, 36–40 years,
and so on, through to 86+ years. Each control subject
was assigned the same index date as the corresponding
DME subject.
Outcomes
Hospitalized MI and CVA events were identified using
inpatient claims as defined by "Place of Service" field
codes = 5 or 6 for "Inpatient hospital" and “Healthcare
Cost Category” field code = 6. The Healthcare Cost Cat-
egory was an additional claims field code used to ensure
that outcomes were identified in an inpatient setting.
The observation period for outcomes was from 1 July
2002 to 31 December 2005. Only the outcomes identified
after a patient’s index date were counted as an event.
Outcome events with admission and discharge dates that
occurred on the same day were excluded because they
are not reliable indicators of true events. Adjacent hos-
pital claims with the same provider identification were
counted as a single hospitalization if they were not sepa-
rated by at least 1 day. Outcome events were identified
in medical claims using the criteria of acute MI (ICD-9-
CM 410.xx) or ischemic CVA (ICD-9-CM 433.x1, 434.
x1, and 436.xx).
Statistical analysis
For each patient, outcome events were recorded together
with total observation time expressed to the nearest day.
Patients were censored at the first occurrence of an
event, end of eligibility, or end of study period. MI and
CVA events were analyzed separately. All statistical
Table 1 Demographic of subjects with DME and age/
gender matched diabetes controls, 1 July 2002 to 31
December 2005
DME subjects Diabetes controls
n % n %
All subjects 3519 100 10557 100
Female 1645 46.7 4935 46.7
Male 1874 53.3 5622 53.3
Age groups
18-29 49 1.4 157 1.5
30-39 217 6.2 591 5.6
40-49 517 14.7 1522 14.4
50-59 1144 32.5 3271 31.0
60-69 937 26.6 2971 28.1
70-79 516 14.7 1521 14.4
80-89 139 3.9 524 5.0
Mean 58 - 59 -
Median 58 - 59 -
SD 12 - 12 -
Region
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(SAS Institute, Cary, NC, USA). Event rates and 95%
confidence intervals (CI) were calculated for each out-
come by age and gender as the number of events per
1000 person-years.
Cox regression was used to compare time to first-event
rates between cohorts, with assumptions for proportional
hazard satisfied. Covariates were added to the model to
adjust for the presence of known risk factors for MI and
CVA during the 183 days of continuous eligibility pre-
ceding the index date. Covariates included history of MI
or CVA prior to index, congestive heart failure (inpatient
only), cardiac arrhythmia (inpatient only), other cerebro-
vascular diseases, hypertension, hyperlipidemia, heart
disease (coronary artery disease), angina, and the prior
use of prescription anticoagulant or antiplatelet drugs. In
addition, a modified Charlson Comorbidity Index (CCI)
score was used as a covariate for the burden of comor-
bidities between the cohorts. And diseases comprising
the CCI were mapped to ICD-9-CM codes [14-16]. In
this study, codes for the outcomes of MI or CVA were
excluded from the index.Midwest 1449 41.2 3485 33.0
Northeast 353 10.0 1184 11.2
South 1430 40.6 4803 45.5
West 287 8.2 1085 10.3
Charlson comorbidity index*
0 294 8.4 3355 31.8
1 1235 35.1 4772 45.2
2+ 1990 56.6 2430 23.0
Eligibility duration Days Years Days Years
Mean 1116 3.1 1085 3.0
Median 1218 3.3 1186 3.2Results
There were 3519 patients identified with DME and
10557 matched diabetic controls with no claims for ret-
inal disorders. Enrollment duration and follow-up time
were similar between the groups (Table 1). The mean
age for DME patients was 58 years with slightly more
men than women. Modified CCI scores were generally
higher in the DME group where more subjects had
scores of≥ 2 (56.6% vs. 23.0%), thus indicating a greater
disease burden (Table 1).SD 371 1.0 398 1.1
Follow-up time
Mean 504 1.4 487 1.3
Median 438 1.2 417 1.1
SD 356 1.0 362 1.0
*Chi-square, p< 0.0001.
DME =diabetic macular edema; SD = standard deviation.Incidence of MI
The rate of MI events was higher in the DME cohort
than in controls (Table 2). There were 94 subjects (2.7%)
that developed a MI in the DME group for a rate of 19.7
MI events/1000 person-years (95% CI: 15.7-23.6). In the
control group, there were 96 MIs (0.9%), for a rate of 6.9
MI events/1000 person-years (95% CI: 5.5-8.2). The rates
of MI were higher in DME patients for both genders
and, within both groups, rates were slightly higher in
men than in women. There was an age-related increase
in event rates in both cohorts, with the DME cohort
higher in each age bracket (Table 2).
After adjustment for risk factors and CCI score, the
rate of MI events was significantly higher in the DME
group than in controls (adjusted HR 2.50, 95% CI: 1.83-
3.41, p< 0.001). The presence of heart disease, history of
MI, and prior use of antiplatelet or anticoagulant drugs
were significant positive predictors of MI in the regres-
sion model (Table 3).Incidence of CVA
The rate of CVA events was also higher in the DME
group than in controls (Table 4). There were 66 subjects
(1.9%) that developed a CVA in the DME group, for a
rate of 13.8 CVA events/1000 person-years (95% CI:
10.5-17.0). In the control group, there were 75 CVAs
(0.7%), for a rate of 5.4 events/1000 person-years (95%
CI: 4.1-6.6).
The rates of CVA were also higher in the DME group
for both genders. In particular, the crude risk of stroke in
men with DME was 2-times higher than in the control
group, and nearly 3-times higher in women with DME.
Table 2 Incidence of AMI in subjects with DME and age/gender matched diabetes controls*, 1 July 2002 to 31
December 2005
DME Subjects Diabetes Controls
Overall n Person-years AMI events rate/1000 PY 95% CI n Person-years AMI events rate/1000 PY 95% CI
All subjects 3519 4778.5 94 19.7 15.7 - 23.6 10557 13981.5 96 6.9 5.5 - 8.2
Females 1645 2220.9 38 17.1 11.7 - 22.5 4935 6502.4 40 6.2 4.3 - 8.1
Males 1874 2557.6 56 21.9 16.2 - 27.5 5622 7479.1 56 7.5 5.5 - 9.4
DME Subjects Diabetes Controls
Age (years) n Person-years AMI events rate/1000 PY 95% CI n Person-years AMI events rate/1000 PY 95% CI
18-29 49 58.5 0 0.0 0.0 - 0.0 157 178.5 0 0.0 0.0 - 0.0
30-39 217 280.9 2 7.1 0.0 - 16.9 591 772.9 3 3.9 0.0 - 8.3
40-49 517 717.6 9 12.5 4.4 - 20.7 1522 1969.7 4 2.0 0.0 - 4.0
50-59 1144 1531.4 28 18.3 11.6 - 25.0 3271 4293.2 17 4.0 2.1 - 5.8
60-69 937 1245.5 28 22.5 14.3 - 30.7 2971 3777.9 31 8.2 5.3 - 11.1
70-79 516 745.0 19 25.5 14.2 - 36.8 1521 2229.4 28 12.6 8.0 - 17.2
80-89 139 199.6 8 40.1 13.1 - 67.0 524 759.9 13 17.1 7.9 - 26.3
*Diabetes controls - diabetes subjects without ophthalmic manifestations, retinal disorders, or vitreous hemorrhage.
DME =diabetic macular edema; AMI = acute myocardial infarction; CVA= cerebrovascular accident; PY = person-years;
CI = confidence interval.
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in both groups, with DME higher in each age bracket ex-
cept for the 80–89 years group (Table 4).
After adjustment for risk factors, the rate of CVA
events after the index date was significantly higher in the
DME group than in the control group (adjusted HR 1.98,
95% CI: 1.39-2.83, p< 0.001). Positive predictors in the
regression model included cardiac arrhythmia, CCITable 3 Adjusted HRs for development of AMI in subjects
with DME compared with age/gender matched diabetes
controls*, 1 July 2002 to 31 December 2005
Reference exposure HR 95% CI p-value
DME versus diabetes controls 2.50 1.83 – 3.41 < 0.001
Covariates†
Angina 1.00 0.59 - 1.71 1.00
Cardiac arrhythmia 1.19 0.75 - 1.87 0.47
Charlson comorbidity index 0.98 0.88 - 1.08 0.63
Congestive heart failure 1.57 0.98 - 2.52 0.06
Heart disease 2.45 1.72 - 3.48 < 0.001
History of AMI 2.62 1.35 - 5.07 0.004
History of CVA 1.37 0.71 - 2.66 0.35
Hyperlipidemia 0.75 0.55 - 1.01 0.06
Hypertension 0.92 0.67 - 1.27 0.62
Other cerebrovascular disease 1.47 0.68 - 3.19 0.33
Prior anti-platelet or anticoagulant 1.93 1.28 - 2.89 0.002
*Diabetes controls - diabetes subjects without ophthalmic manifestations,
retinal disorders, or vitreous hemorrhage.
† All covariates were included in the regression model; bolded text indicates
statistical signficance.
DME =diabetic macular edema; AMI = acute myocardial infarction;
CVA = cerebrovascular accident; CI = confidence interval; HR = hazard ratios.score, history of CVA, hyperlipidemia, and other cere-
brovascular diseases. The presence of hyperlipidemia was
inversely associated with the development of CVA
(Table 5).Discussion
In this analysis of a large insured population of patients
with diabetes, the presence of DME is associated with a
higher incidence of MI and CVA. Adjusted estimates
show a 2.5-fold higher risk of MI and a 2-fold higher risk
of CVA in patients with DME compared with diabetic
patients without retinal disorders. Incident stroke
appeared to be higher in women than men in either
group, which is supported by data from other studies
[17].
Earlier studies have shown that the presence of dia-
betic retinopathy is a predictor of cardiovascular morbid-
ity and mortality [4-8,10]. The Diabetes Control and
Complications Trial reported that tight control of dia-
betes with insulin reduced the 36-month risk of progres-
sion to retinopathy by 76% (95% CI: 62-85%) [18]. In the
case of type 2 diabetes, the UK Prospective Diabetes
Study showed that for every 1% decrease in hemoglobin
A1c (HbA1c), there was a 35% reduction in the risk of
microvascular complications [19].
Other studies have reported cardiovascular outcomes
in DME that appear to support the findings of this study.
The Wisconsin Epidemiologic Study of Diabetic Retinop-
athy (WESDR) examined the relationship between sev-
eral diabetic eye diseases and mortality over a 16-year
period [10]. Patient cohorts with type I or II diabetes
with disease onset before and after the age of 30 years
Table 4 Incidence of CVAs in subjects with DME and age/gender matched controls*, 1 July 2002 to 31 December 2005
DME Subjects Diabetes Controls
Overall n Person-years AMI events rate/1000 PY 95% CI n Person-years AMI events rate/1000 PY 95% CI
All subjects 3519 4778.5 66 13.8 10.5 - 17.0 10557 13981.5 75 5.4 4.1 - 6.6
Females 1645 2220.9 38 17.1 11.7 - 22.5 4935 6502.4 38 5.8 4.0 - 7.7
Males 1874 2557.6 28 10.9 6.9 - 14.9 5622 7479.1 37 4.9 3.3 - 6.5
DME Subjects Diabetes Controls
Age (years) n Person-years AMI events rate/1000 PY 95% CI n Person-years AMI events rate/1000 PY 95% CI
18-29 49 58.5 0 0.0 0.0 - 0.0 157 178.5 0 0.0 0.0 - 0.0
30-39 217 280.9 1 3.6 0.0 - 10.5 591 772.9 0 0.0 0.0 - 0.0
40-49 517 717.6 8 11.2 3.5 - 18.8 1522 1969.7 1 0.5 0.0 - 1.5
50-59 1144 1531.4 18 11.7 6.3 - 17.1 3271 4293.2 17 4.0 2.1 - 5.8
60-69 937 1245.5 21 16.7 9.6 - 23.8 2971 3777.9 18 4.7 2.6 - 6.9
70-79 516 745.0 14 18.8 9.1 - 28.5 1521 2229.4 20 9.0 5.1 - 12.9
80-89 139 199.6 4 19.6 0.7 - 38.6 524 759.9 19 25.1 14.0 - 36.3
*Diabetes controls - diabetes subjects without ophthalmic manifestations, retinal disorders, or vitreous hemorrhage.
DME =diabetic macular edema; CVA= cerebrovascular accident; PY = person-years; CI = confidence interval.
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subjects with DME (n= 92), there was a non-significant
decrease in likelihood of death from ischemic heart dis-
ease compared with similar subjects without DME
(adjusted HR 0.84, 95% CI: 0.43-1.66). In "older-onset"
DME subjects (n = 136), there was a non-significant in-
crease in the likelihood of death from either heart dis-
ease or stroke (adjusted HR 1.10, 95% CI: 0.76-1.58 and
1.17, 95% CI: 0.65-2.10, respectively) [10]. The design
and outcome measures of the WESDR study make itsTable 5 Adjusted HRs for development of CVAs in
subjects with DME compared with age/gender matched
diabetes controls*, 1 July 2002 to 31 December 2005
Reference exposure HR 95%CI p-value
DME versus diabetes controls 1.98 1.39 – 2.83 < 0.001
Covariates†
Angina 0.71 0.32 - 1.58 0.40
Cardiac arrhythmia 1.88 1.12 - 3.16 0.02
Charlson comorbidity index 1.13 1.02 - 1.24 0.02
Congestive heart failure 0.94 0.51 - 1.72 0.84
Heart disease 1.52 0.99 - 2.32 0.06
History of AMI 0.91 0.31 - 2.69 0.87
History of CVA 2.40 1.26 - 4.59 0.01
Hyperlipidemia 0.63 0.44 - 0.91 0.01
Hypertension 1.18 0.81 - 1.70 0.39
Other cerebrovascular disease 2.20 1.03 - 4.71 0.04
Prior anti-platelet or anticoagulant 1.07 0.62 - 1.83 0.81
*Diabetes controls - diabetes subjects without ophthalmic manifestations,
retinal disorders, or vitreous hemorrhage.
† All covariates were included in the regression model; bolded text indicates
statistical signficance.
DME =diabetic macular edema; AMI = acute myocardial infarction;
CVA = cerebrovascular accident; CI = confidence interval; HR = hazard ratios.results difficult to directly compare with the results of
the current study.
Cheung and colleagues examined the relationship be-
tween DR and cardiovascular events in two studies using
data from The Atherosclerosis Risk in Communities
study [6,11]. In the first, investigators performed a pro-
spective cohort study on 1617 patients with diabetes to
quantify the relationship between DR and ischemic
stroke. In subgroup analyses, there was a non-significant
increase in the risk of stroke in subjects with DME
(n= 23, adjusted HR 1.40, 95% CI: 0.54-3.65) [6]. Separ-
ately, Cheung et al. also found that the presence of DR
was associated with 2-times the risk of incident coronary
heart disease events (adjusted HR 2.07, 95% CI: 1.38-
3.11) [11]. However, in subgroup analyses, there was no
change in the risk of coronary events in subjects with
DME (n= 81, adjusted HR 1.00, 95% CI: 0.56-1.79). With
regards to DR, the authors concluded that their findings
supported the role of microvascular disease in the patho-
genesis of heart disease in diabetes. Unfortunately, nei-
ther study was sufficiently powered with DME patients
to detect a significant difference.
Several limitations related to all administrative claims
studies are worth mentioning. Previous studies have
shown that diabetes duration, elevated HbA1c levels and
uncontrolled hypertension are common risk factors for
DR [20] and cardiovascular events [21]. As with most
claims studies, the onset date of a chronic disease is diffi-
cult to determine. The incidence of DME increases with
longer duration of type I diabetes [20]. Diabetes duration
is a predictor for the development of retinopathy and
DME [22,23] and is not measurable in this study. How-
ever, the cohorts in this study were age-matched, which
should minimize any differences between the age of dia-
betes onset and therefore differences in the duration of
Nguyen-Khoa et al. BMC Ophthalmology 2012, 12:11 Page 6 of 7
http://www.biomedcentral.com/1471-2415/12/11diabetes. This does not fully account for residual con-
founding influenced by duration. In this study, HbA1c
results were available for 25% of DME patients and 19%
of controls with mean values of 7.3% and 7.0%, respect-
ively (a sample of patients without diabetes had a mean
value of 5.0%). The American Diabetes Association’s
standards of care establish a HbA1c goal of 7%, so the
subset of patients in this study appears to be within rea-
sonable glycemic control. If this is the case, the differ-
ence in the available data for this study does not appear
to be clinically significant, but glycemic control was not
measured in all patients and therefore was not adjusted
in the regression model. Blood pressure data were not
available to evaluate the effect of uncontrolled hyperten-
sion, but overall hypertension diagnoses were adjusted in
the analysis. In a post-hoc analysis of untreated hyperten-
sion within each cohort, fewer DME patients had hyper-
tension without antihypertensive therapy than did
controls (9.3% vs. 12.7%). Thus, uncontrolled hyperten-
sion alone is unlikely to account for the difference in car-
diovascular events.
Recently, the code combination 362.53 (cystoid macu-
lar edema) plus 250.xx (diabetes mellitus) was found to
have high sensitivity and specificity for DME in a re-
gional study of 22 ophthalmology practices [24]. The
current study did not use cystoid macular edema as a
definition of DME in the inclusion criteria; therefore,
additional subjects with DME may have been excluded.
It is not known how the inclusion of this additional code
would have affected the results. Lastly, administrative
claims cannot differentiate between DME and clinically
significant DME; any divergence in the rates of cardio-
vascular events in these clinical subgroups is not known.
One implication of quantifying baseline rates of cardio-
vascular events in DME is the advent of agents that lo-
cally suppress vascular endothelial growth factors
(VEGF) in the retina but that may also have systemic
effects. Studies have shown that VEGF inhibitors may be
effective in treating DME [25]. However, if VEGF inhib-
ition reaches the systemic circulation, it may play a role
in potentiating cardiovascular complications in diabetes
[26]. As they are adopted into clinical practice, additional
population research will be needed to evaluate the long-
term safety of advanced drugs that target the micro-
vascular complications of diabetes.
Conclusions
To our knowledge, previous studies have lacked suffi-
cient power to estimate the risk of hospitalized MI or
CVA in patients with DME. In this report, both MI and
CVA events were significantly higher in patients with
DME than in diabetic patients without retinal disease.
Microvascular and macrovascular complications of dia-
betes are thought to share pathogenic mechanisms. Thispresents an opportunity for risk communication between
ophthalmologists and their diabetic patients, particularly
if a diagnosis of DME is made. Informed by this analysis,
future studies should be designed that address unmeas-
ured confounders to better characterize the risk of car-
diovascular events in the DME population.
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